Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
08.05.2025 10:50:37

Takeda FY24 Net Profit Down; Lifts Dividend; Sees Higher Profit, But Weak Sales In FY25; Stock Down

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) Thursday reported lower net profit in its fiscal 2024, while profit before tax surged from last year with growth in revenues. Further, the company lifted dividend, and said it projects higher profit for fiscal 2025, but weak core operating profit and revenues.

In pre-market activity on the NYSE, Takeda shares were losing around 3 percent to trade at $14.61.

In the full year, net profit attributable to owners of the company fell 25.1 percent to 107.93 billion yen or $720 million from last year's 144.08 billion yen.

Earnings per share were 67.23 yen or $0.45, lower than prior year's 91.16 yen.

Core net profit was 775.6 billion yen or 491 yen per share, compared to 756.8 billion yen or 484 yen per share last year.

Profit before tax, however, surged 231.7 percent from last year to 175.08 billion yen or $1.17 billion.

Operating profit climbed 60 percent to 342.59 billion yen or $2.29 billion, and core operating profit grew 10.2 percent to 1.16 trillion yen.

Revenue for the year grew 7.5 percent to 4.58 trillion yen or $30.56 billion from last year's 4.26 trillion yen. Revenue grew 2.9 percent at constant currency rates.

Core revenue increased 7.4 percent on a reported basis and 2.8 percent at constant currency rates.

Further, Takeda announced that the annual dividend will be 196 yen per share for fiscal 2024, including year-end dividend of 98 yen per share.

For fiscal 2025, the annual dividend will be 200 yen per share, an year-over-year growth of 2 percent.

For fiscal 2025, the company projects attributable profit of 228.0 billion yen or 144.81 yen per share, a growth of 111.3 percent from the previous year. Core earnings per share would be 485 yen, down 1.2 percent from the prior year.

Operating profit would grow 38.7 percent from last year to 475.0 billion yen, while core operating profit would be down 1.9 percent to 1.14 trillion yen.

Revenue for the year is projected to be down 1.1 percent to 4.53 trillion yen.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu Takeda Pharmaceutical Co Ltd. (spons. ADRs)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien 📈im BX Musterportfolio: Trane Techn., Cintas & Deutsche Boerse mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Trane Technologies
✅ Cintas
✅ Deutsche Boerse

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien 📈im BX Musterportfolio: Trane Technologies, Cintas & Deutsche Boerse mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’668.58 18.60 BNRSDU
Short 12’901.17 13.50 SS4MTU
Short 13’370.90 8.78 B02SIU
SMI-Kurs: 12’269.95 22.05.2025 17:31:45
Long 11’716.05 19.68 BX7SBU
Long 11’419.73 13.19 BXGS2U
Long 10’972.12 8.85 BAOSEU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}